Kairos Pharma, Ltd. Common Stock (KAPA)

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. CL-273 is an investigational, reversible, wild-type-sparing pan-EGFR small-molecule inhibitor discovered using a proprietary AI-driven drug discovery platform and designed to target resistant mutations in EGFR-mutant non-small cell lung cancer. The EGFR-mutated lung cancer treatment market is estimated at $16.2 billion in 2026, with mutations present in approximately 10–15% of NSCLC cases in Western populations and up to 50% in Asian populations. Kairos stated the transaction is expected to be value-accretive and accelerate development of a next-generation, AI-designed EGFR inhibitor, aligning the company with OrbiMed-backed innovation. D. Boral Capital, LLC acted as sole financial advisor.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.

Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival, positioning the assets for potential monotherapy and combination development pending completion of the transaction.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology assets targeting non-small cell lung cancer (NSCLC): CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.

Kairos Pharma (NYSE American: KAPA) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, N.J. The company said Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues advancing its clinical-stage oncology programs.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. The recognition highlights the Company’s work advancing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody being developed to address treatment resistance in metastatic castration-resistant prostate cancer, including positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, released a Letter to Shareholders from CEO John Yu, M.D., outlining 2025 accomplishments and the outlook for 2026. The Company reported positive interim safety and efficacy results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer, showing clinical benefit in 86% of treated patients, with durable progression-free survival and no dose-limiting toxicities. The findings, presented at the European Society for Medical Oncologists Meeting, suggest ENV105 may extend the effectiveness of standard care while maintaining strong tolerability. Kairos continues patient recruitment, with enrollment expected to reach 100 across leading U.S. cancer centers.

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) in men with metastatic castration-resistant prostate cancer. Presented at the European Society for Medical Oncology meeting in Berlin, the study showed clinical benefit in 86% of patients treated with ENV-105 combined with apalutamide, with all responders remaining progression-free for at least four months and half beyond one year. Seven of nine evaluable patients experienced PSA reductions, supporting the therapy’s potential to restore hormone responsiveness. The randomized trial, led by Cedars-Sinai and partner institutions, continues to enroll patients to further evaluate safety and long-term efficacy.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos’s presentation, titled, “Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer” will take place in Berlin, Germany on October 17–21, 2025.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. Among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, with five patients still on treatment and seven of nine showing declines in prostate-specific antigen levels. This exceeded the trial’s target of a 45% improvement in progression-free survival compared with the standard 3.7 months for second- or third-line hormone therapy. The treatment was well tolerated with no dose-limiting toxicities observed. Kairos is hosting a KOL webcast today at 5 p.m. ET / 2 p.m. PT to review the findings with clinical experts.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Kairos Pharma is hosting a virtual KOL (key opinion leader) event to provide perspectives on this data at 5 p.m. ET / 2 p.m. PT today. Interested participants can sign-up to receive the webcast link here.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced it will host a key opinion leader event on Sept. 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu said the event will highlight safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives underscoring the compound’s potential role in addressing cancer drug resistance.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interested participants can sign-up to receive the webcast link here.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, being held Sept. 8–10, 2025, at the Lotte New York Palace Hotel in New York.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp at the World Lung Cancer Conference, taking place Sept. 6–9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp’s presentation, titled “Combination of Osimertinib and Carotuximab for Advanced, EFGR-Mutated Non-Small Cell Lung Cancer Patients,” highlights the combination therapy of ENV105 with osimertinib, with the open-label trial’s primary objective being to evaluate safety and tolerability.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The company will host one-on-one meetings and deliver a presentation available virtually via kairospharma.com.

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Kairos Pharma will participate in on-on-one meetings and present at the meeting which will be available virtually and hosted on the kairospharma.com website.

Momentum in medical and tech-focused small caps continues to explode, led by

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The first-in-class CD105 antagonist showed no dose-limiting toxicities or unexpected adverse events in the first ten patients, and no Grade 3 or 4 toxicities were observed. ENV-105 was well tolerated when combined with apalutamide, a standard hormone therapy. The 100-patient trial is underway at Cedars-Sinai, City of Hope, and Huntsman Cancer Center, with interim efficacy data expected in September 2025. Kairos plans to engage regulators on a potential Phase 3 study.